Rachel Humphrey

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Caroline Robert, L. Thomas, Igor Bondarenko et al. · New England Journal of Medicine · 2011 · 4.5K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Jedd D. Wolchok, Axel Hoos, Steven O’Day et al. · Clinical Cancer Research · 2009 · 3.2K citations

Medicine, Immunology, Oncology +17

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

Steven O’Day, Michele Maio, Vanna Chiarion‐Sileni et al. · Annals of Oncology · 2010 · 510 citations

Pharmacy, Oncology, Pharmacotherapy +14

Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Michael J. Moore, John Hamm, Janet Dancey et al. · Journal of Clinical Oncology · 2003 · 397 citations

Medicine, Oncology, Pharmacology +10

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

Harriet M. Kluger, Hussein A. Tawbi, Maria Libera Ascierto et al. · Journal for ImmunoTherapy of Cancer · 2020 · 280 citations · Full text

Medicine, Immunology, Oncology +16